Medtronic Is Just 1 Year From Dividend King Status. Should You Buy the Stock Before It Gets There?

Medtronic's fiscal 2026 revenue grew 8.4% (5.8% organically), its strongest top-line growth in a decade, led by 9.3% organic growth in cardiovascular. The company expects fiscal 2027 organic revenue growth of 7.25%-7.75%; analysts forecast fiscal 2026-2029 revenue and EPS CAGRs of 5% and 15%. At $87 per share, the stock trades at 18 times this year's earnings and yields 3.4%; after 49 consecutive annual dividend increases, it could reach the 50-year Dividend King threshold next year.

Analysis

The key underwriting question is whether recent growth represents durable share gains or an easier comparison after supply-chain normalization and portfolio changes. A spin-off also makes historical reported growth and EPS less comparable: assess Medtronic plc (MDT) on continuing-business organic growth, margins and cash conversion, not headline EPS alone. Sustained momentum in cardiovascular and neuroscience would matter more than the “Dividend King” milestone; the label may attract income buyers, but it does not itself improve earnings power. Abbott and Boston Scientific are useful cardiovascular benchmarks: if MDT’s growth lags theirs, sector strength may be doing more work than company-specific execution. MiniMed Group (MMED) is now a separate exposure, so MDT shareholders no longer participate in its diabetes business; standalone execution and costs merit separate diligence.

Near term, the dividend record and guidance may support sentiment, but the 1–3 month test is delivery against organic growth expectations and whether that translates into cash flow. Over 6–18 months, product adoption, regulatory execution and competitive positioning will determine if the recovery can sustain a higher multiple. Risks include renewed quality or regulatory setbacks, currency and cost pressure, and GLP-1-related procedure substitution; the latter is not one-way, since better long-run cardiometabolic health could also shift demand. The bullish case is falsified by organic growth deceleration, weaker FCF conversion, or guidance cuts. The article’s valuation and analyst growth estimates are not independently verified here, so “cheap” is not established.

Key Decisions for Investors

• Treat MDT as a measured income-and-recovery position, not a Dividend King momentum trade. Consider entry on broad-market weakness or after results confirm continuing-business organic growth and FCF conversion; avoid adding solely on the dividend-anniversary narrative.
• For the next 1–3 months, track quarterly organic growth by segment, margin trajectory, FCF conversion, and guidance revisions. A growth miss accompanied by weaker cash generation would undermine the recovery thesis even if the dividend is maintained.
• Use Abbott and Boston Scientific as cardiovascular execution comparators. If MDT’s segment growth persistently trails those peers, reassess whether its valuation embeds too much recovery; do not infer company-specific share gains from sector growth alone.
• Keep MMED separate from MDT exposure and evaluate it on standalone operating performance and costs. The article provides insufficient data to recommend a paired trade or to underwrite MMED’s post-spin economics.